Radafaxine

Drug Profile

Radafaxine

Alternative Names: '162; 353162; Bupropion metabolite; GW 353162

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Anxiolytics; Propiophenones; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bipolar disorders; Fibromyalgia; Major depressive disorder; Neuropathic pain; Obesity; Restless legs syndrome

Most Recent Events

  • 03 Aug 2006 Discontinued - Phase-II for Depression in United Kingdom (unspecified route)
  • 06 Dec 2005 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)
  • 22 Apr 2005 Phase-I clinical trials in Neuropathic pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top